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Abstract
Background: Treatment strategies for spinal metastases for myeloma range 
from conservative measures (radiation and chemotherapy) to invasive (surgical). 
Identifying better predictors of overall survival (OS) would help in surgical decision 
making. Analytic morphometrics has been shown to predict survival in oncologic 
patients, and our study evaluates whether morphometrics is predictive of survival 
in patients with multiple myeloma (MM) spinal metastases.
Methods: For this observational retrospective cohort study, we identified 46 patients 
with MM spinal metastases who had undergone stereotactic body radiation therapy. 
OS was the primary outcome measure. Morphometric analysis of the psoas muscle 
was performed using computed tomography scans of the lumbar spine.
Results: OS was statistically correlated with age (P = 0.025), tumor burden 
(P = 0.023), and number of levels radiated (P = 0.029), but not with gender. Patients 
in the lowest tertile of average psoas size had significantly shorter survival compared 
to the highest tertile, hazard ratio (HZ) 6.87 (95% CI = 1.65–28.5, P = 0.008). When 
calculating the psoas size to vertebral body ratio and correlating this measure to OS, 
the lowest tertile again had significantly shorter OS compared to the highest tertile, 
HZ 6.87 (95% CI = 1.57–29.89, P = 0.010); the middle tertile also showed significantly 
shorter OS compared to the highest tertile, HZ 5.07 (95% CI = 1.34–19.10, P = 0.016). 
Kaplan–Meier survival curves were used to visually illustrate the differences in 
survival between different tertiles (Log‑rank test P = 0.006).
Conclusions: Morphometric analysis successfully predicts long‑term survival in 
patients with MM. More research is needed to validate these results and to see if 
these methodologies can be applied to other cancer histologies.
Key Words: Frailty index, morphometric analysis, multiple myeloma mortality, 
oncologic outcomes, spinal metastases
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INTRODUCTION
Multiple myeloma (MM) is a malignancy defined by the 
clonal proliferation of monoclonal plasma cells producing 
M‑protein and ultimately leads to end organ disease 
including hypercalcemia, renal insufficiency, anemia, 
and bone metastases.[28] Bone metastases are common in 
MM and occur in approximately 80–90% of all patients 
throughout the course of the disease.[10,25] Lesions can 
cause severe pain, pathological fractures, and spinal cord 
compression,[11,47] which in turn decrease quality of life and 
each individually increase the risk of mortality.[4,9,44,48,51] 
A randomized control trial of patients with metastatic 
spinal cancer with epidural compression showed that the 
surgical treatment is superior to radiotherapy alone;[38] the 
efficacy of surgery has been confirmed independently in 
the myeloma literature.[2,13,20,53] Spinal metastasis scoring 
systems have been developed[17,30,49,50] due to an increasing 
focus on the outcomes after metastatic surgery,[6,7,24,31,41] 
however, they have consistently underestimated overall 
survival (OS) in patients with MM.[1,33,34,53] Consequently, 
surgical decision making for this population is 
challenging. Despite surgery improving OS, neurological 
outcome, and pain control, oncologic spine surgery 
is resource intensive and has been reported to delay 
adjuvant chemotherapy and radiotherapy.[5,19,22,26,27,46] MM 
patients are also prone to postoperative morbidities, 
which can potentially annihilate any survival benefit.[12] 
Therefore, other objective assessors of fitness for surgery 
are needed to provide insight into which patients are 
appropriate candidates for surgical intervention.
A hallmark of human senescence is frailty, which 
is defined as a “decreased reserve to physiologic 
stressors.”[18,42] Frail patients are at an increased risk 
of postoperative morbidity and mortality;[8,32] however, 
objective measurements of frailty are impractical,[3,35] 
and thus sarcopenia, defined as the loss of overall 
muscle mass, has been used as a surrogate measure to 
successfully predict surgical outcomes,[15,16,21,39,52] including 
after spine surgery.[56] Morphometrics is the study 
methodology of patient characteristics which can identify 
the features of sarcopenia, and thus quantify frailty by 
proxy. Sarcopenic cancer patients have a higher rate of 
postoperative morbidity as well as lower progression‑free 
survival compared to patients not displaying this 
feature.[23,29,37,43] Given that cancer patients constitute 
a high‑risk population, additional tools are required to 
better inform patients, families, and physicians about the 
overall expectations of treatment, whether chemotherapy, 
radiation, surgery, or palliation.
In this study, we applied morphometric analysis of psoas 
size to predict OS in patients with MM metastases to 
the spine. We hypothesized that sarcopenic patients, as 
measured by cross‑sectional psoas size area, would have 
shorter OS.
MATERIALS AND METHODS
This study was approved by our Institutional Review 
Board (IRB #9813). We accessed a registry of spinal 
metastases patients for the period from 2002 to 
2012 who had undergone stereotactic body radiation 
therapy (SBRT) at our institution, and among these, we 
identified all patients who had a primary diagnosis of 
MM, as described by pathology reports or clinical records. 
Of these patients, we identified patients with myeloma 
spine disease that had a computed tomography (CT) 
imaging scan within 6 months of SBRT, or identified the 
most recent CT scan after completion of radiation.
Data sources and variables
Electronic medical records of these patients were the 
primary data source reviewed. Using previously described 
methodology,[54,56] morphometric measurements were 
taken of the psoas muscle at the L4 level. Briefly, a Philips 
ePACS viewer (Royal Philips, Amsterdam, Netherlands) 
was used to measure the cross‑sectional area (in square 
centimeters) of each patient’s psoas muscles. It is 
intuitive that patients who have smaller stature will have 
objectively smaller musculature, but are not necessarily 
more frail; to normalize for stature, we also measured 
the cross‑sectional L4 vertebral body area in the same 
fashion. This methodology was applied to each patient’s 
most recent CT scan of the spine which included the 
psoas and was repeated after radiation. The primary 
outcome measure was OS. Other demographic variables 
such as age, number of levels affected, and total SBRT 
target volume were also considered.
Radiation treatment protocols
At our institution, the gross tumor volume, the clinical 
target volume, and the planning target volume for a given 
patient are all identical; during SRS treatment planning, 
no expansion margin was added to the gross tumor, and 
thus, the gross tumor volume was equal to the planning 
target volume. Margins were created using T2‑weighted 
magnetic resonance images to delineate the spinal cord 
6 mm above and 6 mm below the defined gross tumor 
volume. The entire affected vertebral body was included 
in the target volume. All doses were administered in a 
single fraction. While EBRT is typically used for MM 
spinal metastases at other institutions, all the patients 
in our cohort were carefully selected to receive SBRT/
SRS. Each patient was discussed in a multidisciplinary 
spine tumor board attended by radiation oncologists, 
neurosurgeons, neuroradiologists, and medical 
oncologists. Recommendations regarding whether a 
patient was a suitable candidate for spine SRS were made 
based on consensus opinion.
Statistical analysis
Measurements of the psoas muscle size were divided 
into tertiles according to the value of the psoas area 
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encountered. To account for patient stature, the ratio 
of average psoas size to that patient’s vertebral body 
cross‑sectional area at L4 was considered. The rationale 
here is that the sizes of these two structures should be 
proportional to each other and independent of patient 
stature because the psoas originates from the vertebral 
body; a large and a small person would have a large and 
small psoas and vertebral body, respectively, but the 
psoas/vertebral body ratio should be consistent for both 
patients.[14,45,54] We considered normalizing stature by 
body mass index (BMI), but we were limited by patient 
records. The validity of using psoas to vertebral body 
ratio has been described previously.[14,45,54]
Subsequently, gross tumor volume for SBRT reflects the 
cumulative tumor volume in the spinal column, and 
thus, serves as a surrogate marker of disease burden; this 
hypothesis was tested by dividing the measurements of 
target volumes into quartiles and subsequently calculating 
the hazards of death within each quartile. We hypothesize 
that there was a correlation between the hazards of death 
and increasing tumor volume (i.e., the hazard ratio would 
increase with increasing tumor volume).
The main outcome of interest was OS, which was 
measured from the date of the patient’s selected CT 
scan to the date of death or last follow‑up. We chose to 
measure OS from the date of CT scan and not from the 
date of diagnosis of myeloma or other time point for a 
number of reasons. Most importantly, sarcopenia is a 
time dependent process; we have observed that during 
the course of oncologic disease muscle mass can change, 
such as when patients are undergoing chemotherapy. 
Therefore, measuring death from a time point other than 
the date of CT would be confounding as patient frailty 
and sarcopenia are not measured accurately at that time 
point. Moreover, due to the retrospective nature of this 
study, not many patients will have a CT scan showing 
the psoas muscle at the time of diagnosis of myeloma 
or even from the diagnosis of spinal disease. Therefore, 
to guarantee a consistent point in time and disease as 
well as a large patient sample, it was most logical to start 
from the date of the CT scan. The CT scan chosen was 
either at the time of SBRT or the most recent CT scan 
on record. Patients who did not have a known date of 
death were censored to the date of last follow‑up. We are 
unable to determine cause of death for most patients due 
to incomplete records.
The median OS in days along with the corresponding 
95% confidence interval (CI) was computed for 
all patients, as well as for subsets of interest. Cox 
proportional hazards regression analyses provided an 
estimate of the hazard ratios (HRs) of death. Unadjusted 
HR tested for the likelihood of mortality with any given 
variable of interest. Multivariate analysis of adjusted HR 
controlled for clinically relevant predictors of death along 
with statistically significant predictors in the univariate 
analysis. Kaplan–Meier estimates of time to death were 
categorized by average psoas tertile. The log‑rank test 
was used to assess differences among the three Kaplan–
Meier curves (i.e., tertiles). The Kaplan–Meier curves 
were censored at 2000 days after imaging, which roughly 
correlates to 5‑year mortality. Patients followed beyond 
5 years were considered to be without active systemic 
disease; thus, changes in psoas size secondary to muscle 
remodeling no longer correlated with psoas measurements 
at the time of CT scan. All testing was done at a 
statistical significance level of 0.05. All statistical analyses 
were performed using STATA (version 13.0, College 
Station, TX, USA) and Microsoft Excel.
RESULTS
Participants and descriptive data
Of the patients with MM spine disease within our 
database, we identified 32 patients who had a CT scan 
showing the psoas muscle within 6 months of SBRT. 
We took measurements from the most recent and 
available CT scan of 46 patients. The mean age of the 
SBRT cohort was 63.2 (SD ± 1.9) and for most recent 
CT cohort was 64.8 years (SD ± 1.5yrs) [Table 1]. The 
majority of patients in both populations were male and 
African American. The mean target volume for the SBRT 
cohort was 87.8 cm3 and 83 cm3 for the most recent CT 
cohort, with approximately 43% of the patients in both 
cohorts having single level disease only.
The mean OS and standard deviation for the SBRT cohort 
of 32 patients was 1659.8 days (range, 196–4577), and 
for the 46 recent CT patients it was 1018.6 days (range, 
1–4577 days). Table 2 lists the median OS from the SBRT 
CT scan compared to specific patient demographics, 
with HR for both unadjusted univariate and adjusted 
multivariate analysis. Table 3 exhibits the same data but 
for survival from the most recent CT scan. Multivariate 
analysis adjusted to account for patient age, sex, and 
target volume revealed no significant associations from 
the most recent CT but showed that the CT scan from 
SBRT was associated with age, gender, and number of 
levels treated.
Table 4 shows OS in relation to psoas size, with 
multivariate analysis adjusted to account for interactions 
with patient age, sex, and target volume. For patients 
whose psoas measurements were taken at the time of 
SBRT, those in the lowest (smallest) tertile for average 
psoas size had a significantly shorter OS compared with 
those in the highest tertile: 1157.1 vs 2262.6 days, HR 
4.8 (95% CI = 1.06–21.62, P = 0.041). This association 
was also observed with measurements taken from the 
most recent CT scan, with survival being 754.6 vs 
1592.8 days, HR 6.87 (95% CI = 1.65–28.5, P = 0.008). 
For measurements taken at the time of SBRT, average 
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psoas size was also predictive of OS when comparing the 
lowest tertile with the second tertile: 1157.1 vs 1614.4, 
HR 6.84 (95% CI = 1.72–27.18, P = 0.006). However, 
average psoas size was not predictive of OS in other 
Table 1: Demographic and medical information
Variable CT from SBRT (n=32) Most recent CT (n=46)
Mean age at CT scan±standard deviation (range) 63.2±1.9 64.8±1.5
(40.34‑85.82 years) (40.34‑85.82 years)
Ethnicity, n (%)
African American 20 (62.5%) 26 (56.5%)
Caucasian 10 (31.2%) 18 (39.1%)
South Asian 1 (3.1%) 1 (2.1%)
Hispanic 0 (0%) 0 (0%)
Middle Eastern 1 (3.1%) 1 (2.1%)
Female, n (%) 14 (43.7%) 15 (32.6%)
Male, n (%) 18 (56.2%) 31 (67.3%)
Mean target volume (cm3) ± standard deviation 87.8±11.2 83.0±8.6
Number of levels affected, n (%)
1 14 (43.7%) 20 (43.4%)
2 8 (25.0%) 12 (26.0%)
3 4 (12.5%) 6 (13.0%)
4+ 6 (18.7%) 8 (17.3%)
Table 2: Survival from CT at SBRT and demographic and medical information
Variable n Median survival in 
days (95% CI)
Unadjusted hazard 
ratios (95% CI)
P Adjusted hazard 
ratios (95% CI)
P
Age at CT 32 Increase over 10 years 
(median age=5th decade)
2.18 (1.22, 3.88) 0.008 2.25 (1.19, 4.26) 0.012
Male 18 1937.3±267.3 0.69 (0. 25, 1.87) 0.473 0.13 (0.03, 0.53) 0.005
Female 14 1303.0±270.2 Ref Ref
Target volume (percentile)
>25% 8 2084.0±299.9 Ref Ref
25%‑50% 8 1257.2±235.8 4.44 (0. 83, 23.59) 0.080 3.20 (0.42, 24.51) 0.261
50%‑75% 8 1431.8±583.0 3.80 (0.69, 20.90) 0.124 7.03 (0.82, 59.89) 0.074
>75% 8 1866.1±369.8 2.88 (0.55, 14.95) 0.208 1.98 (0.23, 16.83) 0.532
Number of levels
Single 14 2076.6±321.1 Ref Ref
Multiple 18 1335.6±223.2 3.60 (1.14, 11.34) 0.029 9.08 (1.67, 49.15) 0.010
Table 3: Survival from most recent CT and demographic and medical information
Variable n Median survival in days 
(95% CI)
Unadjusted hazard 
ratios (95% CI)
P Adjusted hazard 
ratios (95% CI)
P
Age at CT 46 Increase over 10 years 
(median age=6th decade)
1.65 (1.06, 2.56) 0.025 1.49 (0.92, 2.41) 0.101
Male 31 1088.3±188.4 1.26 (0.52, 3.03) 0.601 0 0.55 (0.19, 1.60) 0.277
Female 15 872.6±275.9 Ref Ref Ref
Target volume (percentile)
>25% 12 1454.5±301.1 Ref Ref
25%‑50% 11 909.9±221.0 3.79 (0.96, 14.93) 0.056 3.19 (0.53, 18.98) 0.202
50%‑75% 12 918±398.7 3.71 (0.96, 14.30) 0.056 2.39 (0.46, 12.26) 0.293
>75% 11 761.7±268.3 4.71 (1.24, 17.94) 0.023 3.82 (0.71, 20.34) 0.116
Number of levels
Single 20 1242.2±280.1 Ref Ref
Multiple 26 846.7±166.1 2.64 (1.10, 6.34) 0.029 1.73 (0.62, 4.85) 0.292
Surgical Neurology International 2018, 9:172 http://www.surgicalneurologyint.com/content/9/1/172
comparisons in both cohorts. Kaplan–Meier survival 
curves with log‑rank tests for average psoas size tertiles for 
both CT scan times are visualized in Figure 1. Log‑rank 
test reveals a statistically significant difference in survival 
from CT scan at the time of SBRT (P = 0.031), but not 
from the most recent CT scan (P = 0.180).
When calculating the psoas size to vertebral body size 
ratio [Table 4], the only statistically significant results 
were found from the most recent CT scan cohort of 
patients. The lowest tertile again had significantly shorter 
OS compared to the largest tertile: 466.3 vs 1840 days, 
HR 6.87 (95% CI = 1.57–28.89, P = 0.010). In addition, 
the middle tertile developed significantly shorter 
OS (786 days) compared to the highest tertile, HR 
5.07 (95% CI = 1.34–19.10, P = 0.016). Figure 2 shows 
Kaplan–Meier survival curves for average psoas size to 
vertebral body ratio for both CT scan time points. There 
was a statistically significant difference in OS between 
both time points (P < 0.006, log‑rank test). Similar to 
the analysis with psoas size alone, this was adjusted to 
account for patient age, sex, and target volume.
DISCUSSION
Our study results show that morphometric analysis of 
psoas size can be used as a suitable predictor of OS in 
select patients with metastatic spine disease from MM. 
This validates our previously published work on the 
reliability of psoas size in predicting OS in patients with 
lung cancer metastases to the spine.[54] Our work also 
contributes to the emerging literature that morphometrics 
can be successfully used as a method to obtain surrogate 
measures to assess a patient’s overall health.[23,29,37,43,54] 
Further comprehensive studies are needed to identify 
the suitability of morphometrics in earlier stages of 
malignancy, as well as in other histologies.
Limitations
Our study is limited by its retrospective nature and the 
fact that data were acquired in a single institution. We 
are also limited by the electronic medical records, which 
may have intrinsic and hidden bias caused by patient 
selection for intent to treat. Our patient population also 
only includes those who were referred to our center and 
Table 4: Survival from most recent CT and psoas size. Adjusted hazards ratios controlling for age, and target volume
Variable CT at SBRT Most recent CT
n Median survival 
in days (95% CI)
Adjusted hazard 
ratios (95% CI)
P n Median survival 
in days (95% CI)
Adjusted hazard 
ratios (95% CI)
P
Average psoas
1st tertile 11 1157.1 (448.4, 
1865.9)
4.80 (1.06, 
21.62) (1st vs 3rd)
0.041 (1st 
vs 3rd)
16 754.6 (217.3, 
1292.0)
6.87 (1.65, 28.5) 
(1st vs 3rd)
0.008 (1st 
vs 3rd)
2nd tertile 11 1614.4 (1017.7, 
2211.1)
0.70 (0.15, 3.22) 
(2nd vs 3rd)
0.649 (2nd 
vs 3rd)
15 726.0 (334.0, 
1118)
2.10 (0.69, 6.37) 
(2nd vs 3rd)
0.190 (2nd 
vs 3rd)
3rd tertile 10 2262.6 (1406.5, 
3118.6)
6.84 (1.72, 
27.18) (1st vs 2nd)
0.006 (1st 
vs 2nd)
15 1592.8 (932.6, 
2253.1)
1.81 (0.67, 4.84) 
(1st vs 2nd)
0.236 (1st 
vs 2nd)
Ratio of average psoas: 
Vertebral body area
1st tertile 11 1413.6 (454.6, 
2372.5)
4.96 (0.96, 
25.44) (1st vs 3rd)
0.055 (1st 
vs 3rd)
16 466.3 (74.0, 
858.5)
6.87 (1.57, 
29.89) (1st vs 3rd)
0.010 (1st 
vs 3rd)
2nd tertile 11 1382.0 (1032.3, 
1731.6)
2.84 (0.51, 
15.71) (2nd vs 3rd)
0.230 (2nd 
vs 3rd)
15 786.5 (365.8, 
1207.1)
5.07 (1.34, 
19.10) (2nd vs 3rd)
0.016 (2nd 
vs 3rd)
3rd tertile 10 2236.2 (1466.4, 
3005.9)
1.74 (0.51, 5.94) 
(1st vs 2nd)
0.375 (1st 
vs 2nd)
15 1840.0 (1220.8, 
2459.1)
1.35 (0.48, 3.78) 
(1st vs 2nd)
0.564 (1st 
vs 2nd)
Figure 1: Kaplan–Meier survival curve of average psoas size in tertiles
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also successfully underwent SBRT for their metastatic 
spinal disease, thereby excluding other patients in 
earlier stages of disease or those who did not qualify to 
undergo this specific type of radiation. However, given 
the standard practice at our institution, we believe 
that the latter is a small number of patients and that 
our cohort is representative of the population. We are 
limited by patient sample size as well. Some of our 
results approached significance, and during preliminary 
analysis, we noted that as we increased the size of our 
patient cohort, our results became significant. Prospective 
multicenter studies are needed to validate our findings. If 
they are validated, morphometrics could be used to assist 
in patient selection surgery and for tailoring specific 
oncologic treatment regimens.
Interpretation
This study has potential implications for decision 
making in neurosurgery and oncology. While MM 
commonly metastasizes to the spine, its current tumor 
staging system is independent of the extent of osseous 
involvement;[28] therefore, patients at various stages of 
malignancy may have limited or extensive disease burden 
within the spine.
Spine surgery in this population has been shown to 
have the potential to improve patient outcomes,[2,13,20,53] 
but choosing the appropriate patient to take to surgery 
remains difficult given how current prognostic scores 
inaccurately estimate survival.[1,33,34,53]
Any surgery carries inherent risks, and a postoperative 
morbidity may debilitate the patient and hasten demise. 
Therefore, an objective process to assess fitness for 
surgery and/or longevity is beneficial, as it establishes a 
basis for therapeutic decision making. Morphometrics 
is a novel, objective, and comparably simple method to 
obtain a surrogate measure that allows one to assess an 
individual’s overall health for surgery, as evidenced by its 
ability to predict outcomes and overall mortality[23,29,37,43,54] 
and its association with functional status.[36,40]
In our study, the use of the psoas size to vertebral body 
ratio significantly strengthened prognostication. However, 
it is intuitive that patients who have smaller stature 
and therefore objectively smaller musculature are not 
necessarily more frail. By normalizing the psoas muscle 
to the size of the vertebral body we could also account 
for stature and increase the sensitivity of our analysis; 
the middle tertile being at higher risk for death than 
the highest tertile (P = 0.016), and the log‑rank test 
for the Kaplan–Meier survival curves reached statistical 
significance (P = 0.006). Evidence suggests that the 
psoas/vertebral body ratio may be more suitable in 
male patients,[55] an important fact as our population of 
myeloma patients is more than two‑thirds male. Females 
are also at a higher risk of being osteopenic and/or having 
osteoporosis, which may affect the reliability of our 
vertebral body measurements. Research is warranted to 
further explore this relationship.
Generalizability
This study is likely generalizable to all patients with 
MM with metastases to the spinal column. This study 
population is representative of patients who were referred 
to radiation treatment of spinal metastases regardless 
of the decision for surgery, and hence, is not limited by 
operative plan.
CONCLUSION
Morphometric analysis of psoas size can be used in 
predicting survival in select patients with MM metastases 
to the spine. This information can assist in patient 
selection for surgery, as well as to tailor oncologic 
treatments.
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